Charming Shoppes Inc (NASDAQ:CHRS) Move as Institutional Investors’ Sentiment Increased

Coherus BioSciences, Inc. (NASDAQ:CHRS) Logo

Sentiment for Charming Shoppes Inc (NASDAQ:CHRS)

Charming Shoppes Inc (NASDAQ:CHRS) institutional sentiment increased to 1.29 in 2018 Q4. Its up 0.18, from 1.11 in 2018Q3. The ratio is better, as 54 institutional investors started new or increased holdings, while 42 sold and reduced their positions in Charming Shoppes Inc. The institutional investors in our partner’s database now have: 59.12 million shares, down from 59.61 million shares in 2018Q3. Also, the number of institutional investors holding Charming Shoppes Inc in their top 10 holdings decreased from 1 to 0 for a decrease of 1. Sold All: 17 Reduced: 25 Increased: 32 New Position: 22.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $1.00 billion. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

The stock decreased 2.36% or $0.35 during the last trading session, reaching $14.49. About 66,019 shares traded. Coherus BioSciences, Inc. (NASDAQ:CHRS) has risen 53.37% since March 14, 2018 and is uptrending. It has outperformed by 49.00% the S&P500.

Analysts await Coherus BioSciences, Inc. (NASDAQ:CHRS) to report earnings on May, 9. They expect $-0.40 earnings per share, up 45.95 % or $0.34 from last year’s $-0.74 per share. After $-0.92 actual earnings per share reported by Coherus BioSciences, Inc. for the previous quarter, Wall Street now forecasts -56.52 % EPS growth.

Pura Vida Investments Llc holds 1.19% of its portfolio in Coherus BioSciences, Inc. for 211,071 shares. Pier Capital Llc owns 607,596 shares or 1.09% of their US portfolio. Moreover, Hound Partners Llc has 0.59% invested in the company for 2.02 million shares. The New York-based Kohlberg Kravis Roberts & Co. L.P. has invested 0.5% in the stock. Temasek Holdings (Private) Ltd, a Singapore-based fund reported 6.56 million shares.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

Ratings analysis reveals 100% of Coherus Biosciences’s analysts are positive. Out of 2 Wall Street analysts rating Coherus Biosciences, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $25 while the high is $25. The stock’s average target of $25 is 72.53% above today’s ($14.49) share price. CHRS was included in 2 notes of analysts from March 1, 2019. As per Friday, March 1, the company rating was maintained by Maxim Group. Credit Suisse maintained Coherus BioSciences, Inc. (NASDAQ:CHRS) on Thursday, March 7 with “Buy” rating.

More notable recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Seekingalpha.com which released: “FDA to “take action” against branded drug makers using scare tactics to thwart biosimilar competition – Seeking Alpha” on January 10, 2019, also Seekingalpha.com with their article: “Coherus sues Amgen over Humira biosimilar – Seeking Alpha” published on January 25, 2019, Nasdaq.com published: “Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners – Nasdaq” on January 07, 2019. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) were released by: Globenewswire.com and their article: “Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results – GlobeNewswire” published on February 28, 2019 as well as Investingnews.com‘s news article titled: “An Investor’s Overview to Biosimilars – Investing News Network” with publication date: March 13, 2019.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.